Overview

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Status:
Completed
Trial end date:
2007-03-28
Target enrollment:
Participant gender:
Summary
This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Rosiglitazone